Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping

Status Recruiting

Clinical Trial Summary

CACT-IHF aims to evaluate the clinical efficacy and safety of Qishen Yiqi Dripping Pills in treating ischemic heart failure. Meeting the diagnosis, inclusion and exclusion criteria, the study plans to recruit 640 cases from 35 upper class hospitals in China, who are divided into two groups (treatment and control group) by central randomization service. The treatment group will be administrated with one bag of Qishen Yiqi Dripping Pills (0.52g/bag) three times a day in addition to standardized western medications. Whereas the control group will be given one bag of Qishen Yiqi Dripping Pills dummy (0.52g/bag) three times a day in addition to standardized western medications. Efficacy indicators include primary indicator (6 minute walk test) and secondary indicators: composite endpoint consisting of all-cause death, emergency/re-admission to hospital due to HF, frequency of re-admission due to cardiovascular disease, acute coronary syndrome, severe arrhythmia, cardiac shock, revascularization, stroke, pulmonary embolism and peripheral vascular incidences, etc.; Brain Natriuretic Peptide; echocardiography; cardiothoracic ratio; NYHA cardiac function classification; Minnesota life quality scale; scores from the four traditional chinese medicine (TCM) diagnostic methods). Other indicators include blood cholesterol, triglyceride, high density cholesterol and low density cholesterol. Safety indicators include blood pressure, heart rate, blood and urine routine tests, liver and renal function tests, serum electrolytes, electrocardiogram and adverse events. All of the patients will receive interventional drug treatment for 6 months. Follow up is needed on the 1st, 3rd, 6th, 9th, 12th month after recruitment. All patients will be followed up until the end of study (Refers to the 12th month of the last case recruited into the study).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01555320
Study type	Interventional
Source	State Administration of Traditional Chinese Medicine of the People's Republic of China
Contact	Yazhu Hou, Dr.
Phone	8622-27432325
Email	mreleven@163.com
Status	Recruiting
Phase	N/A
Start date	March 2012
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02240940` - PARACHUTE China Approval Trial	N/A
Completed	`NCT00846001` - Resynchronization Surgery Combined Unified Efficacy	Phase 3
Recruiting	`NCT05566600` - Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure	Early Phase 1
Active, not recruiting	`NCT01961726` - Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure	Phase 1/Phase 2
Terminated	`NCT00102128` - Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.	Phase 2
Not yet recruiting	`NCT03491969` - Clinical Study of Lipoic Acid on Ischemic Heart Failure	Phase 4
Recruiting	`NCT02875639` - A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome)	Phase 2
Completed	`NCT02700880` - LifeVest Wearable Cardioverter Defibrillator WEARIT-III Registry
Active, not recruiting	`NCT01643590` - Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.	Phase 2
Active, not recruiting	`NCT02115568` - Registry to Assess Safety for Subjects That Have Completed a Juventas Sponsored HF Protocol Under IND # 14203	N/A
Recruiting	`NCT03206593` - Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure	N/A
Enrolling by invitation	`NCT01709279` - Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure	N/A
Not yet recruiting	`NCT06258447` - CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure — CACT-IHF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms